Physician profile
Lucy Chang
NPI 1629137872
$5,119.67
in general payments reported to CMS, 2019-2025
42 companies · $958 in 2025
The $958 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $227 · 2021: $498 · 2022: $719 · 2023: $913 · 2024: $877 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $911.67 | 2019-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $615.58 | 2019-2025 | |
| Lilly USA, LLC | $376.55 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $375.01 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.38 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $252.81 | 2025 | Airsupra, Bevespi Aerosphere |
| Dexcom, INC. | $171.79 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $170.76 | 2020-2023 | Trelegy Ellipta |
| Amgen INC. | $164.86 | 2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $160.20 | 2022 | |
| Phathom Pharmaceuticals, INC. | $151.38 | 2024-2025 | Voquezna |
| W. L. Gore & Associates, INC. | $132.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $113.19 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $113.02 | 2023 | Quviviq |
| Exact Sciences Corporation | $102.31 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.